Cover Image
市場調查報告書

子宮內膜異位症:開發中產品分析

Endometriosis - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 232822
出版日期 內容資訊 英文 132 Pages
訂單完成後即時交付
價格
Back to Top
子宮內膜異位症:開發中產品分析 Endometriosis - Pipeline Review, H2 2016
出版日期: 2016年09月14日 內容資訊: 英文 132 Pages
簡介

所謂子宮內膜異位通常是子宮內部的組織(子宮內膜)擴大到子宮外部這樣的疾病,常會伴隨疼痛。主要症狀有骨盤痛及月經痙攣、發炎、不孕症、異常出血等。致病因子有排尿不順、骨盤內感染症病歷、家族病史等。主要治療藥有非甾體抗炎藥物(NSAID)和口服避孕藥,黃體激素物質等。

本報告提供全球各國治療子宮內膜異位症所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

子宮內膜異位症概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

子宮內膜異位症:企業開發中的治療藥

子宮內膜異位症:大學/機關研究中的治療藥

子宮內膜異位症:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

子宮內膜異位症:企業開發中的產品

子宮內膜異位症:大學/機關研究中的產品

子宮內膜異位症的治療藥的開發企業

  • AbbVie Inc.
  • Addex Therapeutics Ltd
  • APAvadis Biotechnologies Srl
  • Astellas Pharma Inc.
  • Bayer AG
  • Dongkook Pharmaceutical Co., Ltd.
  • ElexoPharm GmbH
  • EndoCeutics, Inc.
  • Euroscreen S.A.
  • Evotec AG
  • Forendo Pharma Limited
  • GlaxoSmithKline Plc
  • Kissei Pharmaceutical Co., Ltd.
  • Lipicard Technologies Limited
  • 日本新藥
  • Orphagen Pharmaceuticals, Inc.
  • Philogen S.p.A.
  • Repros Therapeutics Inc.
  • SK Chemicals Co., Ltd.
  • 武田藥品工業
  • ValiRx Plc

子宮內膜異位症:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

子宮內膜異位症:最近的開發平台趨勢

子宮內膜異位症:暫停中的計劃

子宮內膜異位症:開發中止的產品

子宮內膜異位症:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8457IDB

Summary

Global Markets Direct's, 'Endometriosis - Pipeline Review, H2 2016', provides an overview of the Endometriosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Endometriosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Endometriosis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Endometriosis
  • The report reviews pipeline therapeutics for Endometriosis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Endometriosis therapeutics and enlists all their major and minor projects
  • The report assesses Endometriosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Endometriosis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Endometriosis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Endometriosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Endometriosis Overview
  • Therapeutics Development
    • Pipeline Products for Endometriosis - Overview
    • Pipeline Products for Endometriosis - Comparative Analysis
  • Endometriosis - Therapeutics under Development by Companies
  • Endometriosis - Therapeutics under Investigation by Universities/Institutes
  • Endometriosis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Endometriosis - Products under Development by Companies
  • Endometriosis - Products under Investigation by Universities/Institutes
  • Endometriosis - Companies Involved in Therapeutics Development
    • AbbVie Inc
    • Addex Therapeutics Ltd
    • APAvadis Biotechnologies Srl
    • Astellas Pharma Inc.
    • Bayer AG
    • Dongkook Pharmaceutical Co., Ltd.
    • ElexoPharm GmbH
    • EndoCeutics, Inc.
    • Enteris BioPharma, Inc.
    • Euroscreen S.A.
    • Evotec AG
    • Forendo Pharma Limited
    • GlaxoSmithKline Plc
    • Kissei Pharmaceutical Co., Ltd.
    • Lipicard Technologies Limited
    • Luye Pharma Group Ltd.
    • Nippon Shinyaku Co., Ltd.
    • Orphagen Pharmaceuticals, Inc.
    • Philogen S.p.A.
    • Repros Therapeutics Inc.
    • SK Chemicals Co., Ltd.
    • Takeda Pharmaceutical Company Limited
    • ValiRx Plc
  • Endometriosis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • acolbifene hydrochloride + GnRH Agonist + prasterone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASP-1707 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BAY-1128688 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bentamapimod - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug to Inhibit C-Jun for Endometriosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs for Endometriosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs for Endometriosis and Uterine Fibroids - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • elagolix sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • epelsiban besylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ESN-364 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EVE-104 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FP-5677 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • goserelin biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • goserelin ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KLH-2109 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • leuprolide acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LT-6121 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MIA-602 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Antagonize Prolactin Receptor for Endometriosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NS-580 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptides for Endometriosis and Hepatic Tumor - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptides to Inhibit Aminopeptidase A for Endometriosis and Hepatic (Liver) Tumor - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PGL-2001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein for Endometriosis and Ovarian Hyperstimulation Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • relugolix - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SKI-2670 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize FSH Receptor for Women's Health - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize GnRH for Endometriosis, Male Health, Uterine Fibroids and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize Steroidogenic Factor-1 for Endometriosis, Cancer and Cushing's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit 17 Beta-HSD1 for Endometriosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit 17 Beta-Hydroxysteroid Dehydrogenase Type1 for Endometriosis and Estrogen Dependent Cancers - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit CD147 for Immunology, Oncology, Endometriosis and Arthritis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SR-16234 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • telapristone acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Tetravil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • triptorelin biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VAL-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vilaprisan - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VPE-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VPEA-004 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Endometriosis - Dormant Projects
  • Endometriosis - Discontinued Products
  • Endometriosis - Product Development Milestones
    • Featured News & Press Releases
      • Aug 05, 2016: Evotec Achieves Clinical Development Milestone as Part of Its Multi-Target Alliance with Bayer in Endometriosis
      • Jul 06, 2016: ObsEva Receives Clearance from US FDA to Initiate Phase 2b Study EDELWEISS with OBE2109, a Potentially Best-in-Class Oral GnRH Antagonist, for the Treatment of Endometriosis
      • Mar 31, 2016: ValiRx is exhibiting and presenting at the prestigious AACR
      • Feb 10, 2016: AbbVie Announces Positive Top-Line Results From Second Phase 3 Study Investigating Elagolix in Patients with Endometriosis
      • Dec 21, 2015: Repros Updates Proellex Program
      • Mar 24, 2015: Bayer to present new preclinical, early clinical and epidemiological data on Vilaprisan at 62nd Annual Scientific Meeting, March 25-28, 2015, in San Francisco, CA
      • Feb 26, 2015: New Endometriosis Patent Grant for ValiRx
      • Jan 15, 2015: Clinical Trial and Development Update on VAL201 for oncology indications
      • Jan 08, 2015: Abbvie Announces Positive Top-Line Results From Phase 3 Study Of Investigational Medicine Elagolix In Patients With Endometriosis
      • Jun 20, 2014: Euroscreen ESN364 drug candidate presented at the ICE/ENDO Meeting
      • Apr 01, 2014: ValiRx Provides Updated On Anti-cancer Therapeutic VAL201
      • Mar 13, 2014: New drug candidate showed efficacy in human endometriosis samples
      • Dec 18, 2013: Euroscreen Initiates Phase I Clinical Trial For ESN364
      • Oct 03, 2013: ValiRx Files Phase IB/dose escalation study for VAL201
      • Aug 29, 2013: Neurocrine Biosciences Announces the Start of Second Phase III Study of Elagolix in Endometriosis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Endometriosis, H2 2016
  • Number of Products under Development for Endometriosis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Endometriosis - Pipeline by AbbVie Inc, H2 2016
  • Endometriosis - Pipeline by Addex Therapeutics Ltd, H2 2016
  • Endometriosis - Pipeline by APAvadis Biotechnologies Srl, H2 2016
  • Endometriosis - Pipeline by Astellas Pharma Inc., H2 2016
  • Endometriosis - Pipeline by Bayer AG, H2 2016
  • Endometriosis - Pipeline by Dongkook Pharmaceutical Co., Ltd., H2 2016
  • Endometriosis - Pipeline by ElexoPharm GmbH, H2 2016
  • Endometriosis - Pipeline by EndoCeutics, Inc., H2 2016
  • Endometriosis - Pipeline by Enteris BioPharma, Inc., H2 2016
  • Endometriosis - Pipeline by Euroscreen S.A., H2 2016
  • Endometriosis - Pipeline by Evotec AG, H2 2016
  • Endometriosis - Pipeline by Forendo Pharma Limited, H2 2016
  • Endometriosis - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Endometriosis - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2016
  • Endometriosis - Pipeline by Lipicard Technologies Limited, H2 2016
  • Endometriosis - Pipeline by Luye Pharma Group Ltd., H2 2016
  • Endometriosis - Pipeline by Nippon Shinyaku Co., Ltd., H2 2016
  • Endometriosis - Pipeline by Orphagen Pharmaceuticals, Inc., H2 2016
  • Endometriosis - Pipeline by Philogen S.p.A., H2 2016
  • Endometriosis - Pipeline by Repros Therapeutics Inc., H2 2016
  • Endometriosis - Pipeline by SK Chemicals Co., Ltd., H2 2016
  • Endometriosis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Endometriosis - Pipeline by ValiRx Plc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Endometriosis - Dormant Projects, H2 2016
  • Endometriosis - Dormant Projects (Contd..1), H2 2016
  • Endometriosis - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Endometriosis, H2 2016
  • Number of Products under Development for Endometriosis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top